 Vyant Bio NASDAQ:VYNT Inc announced its third-quarter 2021 strategic and business updates, reporting total revenue of 1.5 million for the three months ending September 30, 2021, compared to 1.9 million in 3Q 2021. During the quarter, the New Jersey-based company announced that it appointed Robert Fremeau as the new chief scientific officer, who will be lead Vyant Bio NASDAQ:VYNTs research and development programs. 